Navigation Links
Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Date:4/1/2011

BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat.  Results from SILEN-C1 show a sustained viral response (SVR) in 71 to 83 percent of treatment-naive patients who received BI 201335 once-daily plus the current standard-of-care (SOC) [pegylated interferon (PegIFN) and ribavirin (RBV)].

Results from SILEN-C2 show an SVR in 28 to 41 percent of treatment-experienced patients who received BI 201335 once-daily plus PegIFN and RBV.

"SILEN-C1 and 2 have shown positive Phase 2 results in a broad range of HCV patients," said Peter Piliero, M.D., executive director, Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "The current standard-of-care in HCV is not effective for enough patients. Protease inhibitors such as BI 201335 represent potential new options to improve outcomes and the possibility to shorten the duration of treatment for HCV disease."

"Boehringer Ingelheim is continuing its long heritage in virology and commitment to develop new medicines for HCV," continued Piliero. "BI 201335 is part of BI's growing HCV portfolio, which is being investigated with the goal of improving treatment and cure rates for HCV patients.  We are excited that we will commence our Phase 3 trial program with BI 201335 in the near future, based on the results of these Phase 2 studies."

(Oral abstract #60) SILEN-C1: Sustained Virologic Response (SVR) and Safety of BI 201335 Combined with Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Genotype-1 HCV InfectionIn this double-blind, randomized, placebo-controlled trial, 429 treatment-na
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , FARUM, Denmark and ... On July 31, 2015 the US Food and Drug Administration ... of Major Depressive Disorder in adult patients who have failed ... current episode. TMS is a non-invasive technique for stimulating neural ... suffering from Major Depressive Disorder. The procedure has been proven ...
(Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
(Date:8/27/2015)... Aug. 27, 2015  A recent study by ... Journal, compared the Arthrosurface HemiCAP® Wave implant, which ... an "onlay" design implant for isolated patellofemoral disease. ... function and pain scores, none of the patients ... (OA). However, 53% of the patients in the ...
Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES ... recently announced that it will be devoting an entire short segment to the subject ... people around the globe on a daily basis, but recent advancements in medical science ...
(Date:8/28/2015)... Las Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... is announcing its decision to make the purchase of CPAP equipment more affordable by ... This offer includes all types of CPAP products and orders of any size. My ...
(Date:8/28/2015)... , ... August 28, 2015 , ... With the goal ... returned for the second year to the Adams County Fairgrounds in Mendon, IL on ... to raise money to support music education in the underfunded school districts of Mendon ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... Philadelphia, PA, 6 April 2010 - Attention-deficit/hyperactivity disorder (ADHD) ... affecting children and adolescents. Children with ADHD are excessively ... and in school. Problems inhibiting behavior are a common ... treated with stimulant medications, behavioral approaches or a combination ...
... ... to promote organic seed research and conserve crop genetic diversity – ultimately ensuring a ... ... The CLIF BAR Family Foundation today announced a $500,000 grant to promote organic seed ...
... more children today are surviving cancer than ever before, young ... a decade less, on average, than the general population, according ... School of Public Health. Depending on the type of ... years to more than 17 years, the scientists report in ...
... from the Department of Exercise and Sports Sciences, University ... involving both men, women and children, who were divided ... the studies are so remarkable that the Scandinavian ... publishing a special edition issue entitled "Football for Health" ...
... 65 percent in U.S., study finds , TUESDAY, April ... intentional abuse of prescription sedatives, tranquilizers and other painkilling ... research reveals. , Hospital stays from an unintentional overdose ... (such as Valium and Ativan) jumped 37 percent between ...
... ... III in Webinar Series on Opportunities for Improvement in Various Stages of the RN ... ... human capital research firm, will host a webinar titled “When Engagement Isn’t Enough: Retaining ...
Cached Medicine News:Health News:Synergy between behavioral and pharmacologic interventions for ADHD 2Health News:CLIF BAR Family Foundation Commits $500,000 to Protect and Promote Organic Seed and Farming 2Health News:Childhood cancer survivors may face shortened lifespan, study reveals 2Health News:Childhood cancer survivors may face shortened lifespan, study reveals 3Health News:Childhood cancer survivors may face shortened lifespan, study reveals 4Health News:Scientists: Soccer improves health, fitness and social abilities 2Health News:Scientists: Soccer improves health, fitness and social abilities 3Health News:Scientists: Soccer improves health, fitness and social abilities 4Health News:Prescription Drug Abuse Sending More to Hospitals 2Health News:Prescription Drug Abuse Sending More to Hospitals 3Health News:Morehead Presents Webinar on ,“When Engagement Isn't Enough: Retaining RNs”, 2
... a FAM-labeled probe that is designed to detect ... In addition, this ASR contains primers, a Texas ... sequence. This ASR requires an instrument that can ... as the Cepheid SmartCycler System. The Cepheid Analyte ...
... SpideRX Embolic Protection Device features the ability ... cross the lesion and a pre-loaded nitinol ... and recovery. Offering a fully rapid exchange ... use in the indicated applications:, Carotid Indication ...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Controls for APC Resistance / Factor V Leiden Functional Assay...
Medicine Products: